# Harry Kalms

> Harry Kalms is a seed investor at CPT Capital (London) backing Biotechnology and Commercial. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [CPT Capital](https://shizune.co/investors/profile/cpt-capital)
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Oct 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/harry-kalms/

Harry Kalms is a seed investor at CPT Capital in London focused on Biotechnology and Commercial. Harry Kalms

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Commercial | 1 | 50% |
| Life Science | 1 | 50% |
| 3D Technology | 1 | 50% |
| Food Processing | 1 | 50% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series C | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 1 | 50% |
| United Kingdom | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Asterix Foods | Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel. | $4.2M | Seed | Oct 08, 2025 |  |
| ENOUGH | ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. ​ | $43.9M | Series C | Aug 17, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 1 deal together
- [Grok Ventures](https://shizune.co/investors/profile/grok-ventures) — VC Fund, 1 deal together
- [Israel Innovation Authority](https://shizune.co/investors/profile/israel-innovation-authority) — VC Fund, 1 deal together
- [ReGen Ventures](https://shizune.co/investors/profile/regen-ventures) — VC Fund, 1 deal together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 1 deal together
- [World Fund](https://shizune.co/investors/profile/world-fund) — VC Fund, 1 deal together

## About CPT Capital

VC Fund · London, United Kingdom

CPT Capital is an investment firm that invests in visionary founders. Their mission is to drive the food and materials technology revolution by replacing animals in the supply chain.

2 contacts available at CPT Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Debbie Jones | Chief Financial Officer | https://shizune.co/investors/profile/debbie-jones-311e |
| Harry Kalms | Senior Investment Associate | https://shizune.co/investors/profile/harry-kalms |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Harry Kalms invest in?

Harry Kalms invests primarily in Biotechnology, Commercial and Life Science startups, most often at Seed and Series C stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Harry Kalms last invest?

The most recent investment recorded for Harry Kalms closed in Oct 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co